

1 **Novel osteoconductive β -tricalcium phosphate/poly(L-lactide-co-e-**
2 **caprolactone) scaffold for bone regeneration: a study in a rabbit**
3 **calvarial defect**

4

5 **Pihlman, Hanna¹**

6 **Keränen, Pauli¹**

7 **Paakinaho, Kaarlo^{2, 5}**

8 **Linden, Jere¹**

9 **Hannula, Markus³**

10 **Manninen, Iida-Kaisa⁴**

11 **Hyttinen, Jari²**

12 **Manninen, Mikko⁵**

13 **Laitinen-Vapaavuori, Outi¹**

14

15

16 **1 Faculty of Veterinary Medicine, University of Helsinki, Finland**

17 **2 Faculty of Medicine and Life Sciences, Biomeditech, University of Tampere, Finland**

18 **3 Faculty of Biomedical Science and Engineering, Tampere University of Technology, Finland**

19 **4 Muonio Health Center, Muonio, Finland**

20 **5 Orton Orthopaedic Hospital, Helsinki, Finland**

21

22 **Corresponding author**

23 **hanna.pihlman@helsinki.fi, phone +358 400459932**

24

25 **Abstract**

26


27 The advantages of synthetic bone graft substitutes over autogenous bone grafts include abundant graft volume, lack
28 of complications related to the graft harvesting, and shorter operation and recovery times for the patient. We studied a
29 new synthetic supercritical CO₂-processed porous composite scaffold of β -tricalcium phosphate and poly(L-lactide-co-
30 caprolactone) copolymer as a bone graft substitute in a rabbit calvarial defect.

31 Bilateral 12 mm diameter critical size calvarial defects were successfully created in 18 rabbits. The right defect was
32 filled with a scaffold moistened with bone marrow aspirate, and the other was an empty control. The material was assessed
33 for applicability during surgery. The follow-up times were 4, 12, and 24 weeks. Radiographic and micro-CT studies and
34 histopathological analysis were used to evaluate new bone formation, tissue ingrowth, and biocompatibility.

35 The scaffold was easy to shape and handle during the surgery, and the bone-scaffold contact was tight when visually
36 evaluated after the implantation. The material showed good biocompatibility and its porosity enabled rapid invasion of
37 vasculature and full thickness mesenchymal tissue ingrowth already at four weeks. By 24 weeks, full thickness bone
38 ingrowth within the scaffold and along the dura was generally seen. In contrast, the empty defect had only a thin layer of
39 new bone at 24 weeks. The radiodensity of the material was similar to the density of the intact bone.

40 In conclusion, the new porous scaffold material, composed of microgranular β -TCP bound into the polymer matrix,
41 proved to be a promising osteoconductive bone graft substitute with excellent handling properties.

42



43

44 **1 Introduction**

45

46 Large critical size bone defects cannot heal without the osteoinductive or osteoconductive properties of a bone graft or its
47 substitute [1]. Today, autologous bone grafts are considered to be the gold standard since they have good osteoinductive,
48 osteoconductive, and osteogenic properties and induce no rejection in the body of the patient [2-4]. However, autologous
49 bone grafting also has disadvantages, such as donor site pain, nerve or other soft tissue injuries, blood loss or hematoma
50 formation, and also limited graft volume [2, 5-8]. In iliac crest bone graft harvesting procedures, the minor complication
51 rate has varied between 7% and 39% and the major complication rate between 0.8% and 25% [3, 8].

52 Synthetic bone graft materials have been developed to minimize the complications related to autogenous bone graft
53 harvesting. An optimal bone graft substitute should show good biocompatibility, facilitate tissue ingrowth, and stimulate
54 new bone formation [1, 2]. The biodegradability of the material needs to be on a level where it gives enough structural
55 support but also allows new bone regeneration to replace the decomposing material [1, 2, 9]. Commercially available
56 bone grafts are either brittle ceramics, hard bioactive glass particles, or paste-like fillings [10, 11] that offer limited options
57 in terms of shaping or tailoring the synthetic graft according to operational need.

58 An option to increase the operational freedom for the surgeon and the resilience of ceramic-based bone graft substitute
59 materials, is to use composite techniques to bind microgranular ceramic particles into a solid form with a biodegradable
60 polymer matrix and to further foam the composite material into a structure that mimics bone. An example of such a
61 structure is a supercritical CO₂ -foamed composite of β -tricalcium phosphate and poly(L-lactide-co-caprolactone)
62 copolymer (β -TCP/PLCL). The ceramic component, β -tricalcium phosphate (β -TCP), shows a similar composition and
63 calcium phosphorus ratio as the mineral phase of native bone. Interestingly, its ability to promote bone healing was
64 demonstrated already a hundred years ago [12]. Recently, the osteoconductive properties and biocompatibility of β -TCP
65 have been shown in experimental and clinical studies [13-15]. β -TCP is mainly degraded in the body by dissolution, but
66 a small amount of degradation is mediated by osteoclasts [16].

67 The second component, poly(L-lactide-co- ϵ -caprolactone), is a copolymer of lactide and ϵ -caprolactone, and its
68 biocompatibility has been demonstrated in various studies [17-19]. The biodegradability of the polymer is based on non-
69 enzymatic hydrolysis [19]. The porous and flexible nature of the β -TCP/PLCL scaffold enables an easy addition of bone
70 marrow aspirate into the scaffold which in turn enhances its osteoinductive and osteogenic properties [11, 20]. Notably,
71 bone marrow aspiration can be done percutaneously, for example, from the iliac crest, which has a significantly lower
72 complication rate when compared with bone graft harvesting from the iliac crest [21].

73 The main aim of the present study was to evaluate the tissue ingrowth, new bone formation, biocompatibility, and
74 biodegradability of a new β -TCP/PLCL material in a 12 mm critical size calvarial defect in rabbits. In addition, we
75 evaluated the applicability of the material during surgery.

76

77 **2 Materials and Methods**

78

79 **2.1 β -TCP/PLCL composite scaffold**

80

81 Bioabsorbable porous composite scaffolds were manufactured by melt-mixing polylactide-co- ϵ -caprolactone 70L/30CL
82 (PLCL; Purasorb PLC 7015, Corbion Purac Biomaterials, Gorinchem, The Netherlands) and β -tricalcium phosphate (β -
83 TCP; Plasma Biotal Ltd., Buxton, United Kingdom) with the mixing ratio of 50 wt-% of β -TCP in the composite. The

84 composite rods were foamed by supercritical carbon dioxide into porous composite blocks with the porosity of 65% and
85 an average pore size of $380 \mu\text{m} \pm 150 \mu\text{m}$ measured by μ -CT (MicroXCT-400, Zeiss) with a resolution of $5 \mu\text{m}$. After
86 foaming, the blocks were cut into $2.4 \text{ mm} (\pm 0.5 \text{ mm})$ thick plates and gamma-irradiated for sterility with a minimum
87 dose of 25 kGy.

88

89 **2.2 Surgical procedures**

90

91 The study and surgical protocols were approved by the Finnish Animal Experiment Board (ESAVI/5398/04.10.07/2014).
92 Furthermore, the study complied with Finnish legislation on animal experimentation and the European Union Directive
93 2010/63/EU. All efforts were taken to minimize the suffering and distress of the rabbits during the study.

94 A total of twenty female New Zealand White Rabbits aged from 18 to 32 weeks were operated. The rabbits were
95 sedated with subcutaneous injection of medetomidine 0.3 mg/kg (Domitor® 1 mg/mL , OrionPharma) and ketamine 35
96 mg/kg (Ketador vet® 100 mg/mL , Richter Pharma). All the rabbits received 0.9% sodium chloride with 5% glucose 10
97 mL/kg/h intravenously during the procedure. Preoperatively, 15 mg/kg trimethoprim-sulfa (Duoprim® $200/40 \text{ mg/mL}$,
98 Intervet International), 4 mg/kg carprophen (Norocarp® 50 mg/mL , Norbrook Laboratories), and 0.03 mg/kg
99 buprenorphine (Bupaq® 0.3 mg/mL , Richter Pharma) were given intravenously. Anesthesia was maintained with 1.5%
100 isoflurane (IsoFlo® vet 100% , Abbott Laboratories) via endotracheal tube or mask. If needed, intravenous boluses of
101 ketamine 10 mg/kg or propofol (Vetofol® 10 mg/mL , Norbrook Laboratories) 2 mg to 5 mg/rabbit were given to effect.
102 The top of the head and the lateral side of the stifle joint were clipped and prepared for aseptic surgery. Strict aseptic
103 surgical protocols were followed during the procedure.

104 A midline sagittal skin incision was made from behind the ears to the level of the first cervical vertebrae. The
105 periosteum was incised from the midline and elevated to reveal the bone surface of the parietal bones. A custom-made 12
106 mm diameter trephine was used to mark the round defects on both parietal bones. Bicortical craniotomy was made by
107 using a 2.5 mm and 4 mm diameter burr with continuous saline irrigation [Electric Pen Drive (EPD), DePuy Synthes].

108 During the operation, scaffold plates were press-cut into 12 mm diameter discs with a trephine from prefabricated
109 oversized plates. Bone marrow aspirate was collected with a 2 cc syringe and 21 G needle from a 3.2 mm diameter
110 monocortical drill hole in the lateral femoral condyle and used for moistening the scaffold. Moistening was performed by
111 squeezing the scaffold in a sterile elastic pouch filled with aspirate so that the porous structure would be fully moistened.
112 The bone marrow aspirate was used to promote osteogenic and osteoinductive properties. The right defect was filled with
113 scaffold by bending it along the shape of the skull. The left one served as an empty control. The surgical field was then
114 flushed with saline before closure. The periosteum and the skin were closed in layers with $4\text{-}0$ poliglecaprone 25
115 (Monocryl®, Ethicon).

116 Postoperatively, a subcutaneous injection of atipamezole (Antisedan® 5 mg/mL , OrionPharma) was given. For
117 control of postoperative pain, the rabbits received a subcutaneous injection of buprenorphine 0.03 mg/kg two to three
118 times a day for three days and carprophen 4 mg/kg once a day for two days. The rabbits also received a subcutaneous
119 injection of metoclopramide 0.2 mg/kg (Primperan® 5 mg/mL , Sanofi) to increase the intestinal motility twice a day for
120 one day. Hay and water were freely available. After two weeks of restricted cage rest, the rabbits were removed to a large
121 group housing area.

122 Two rabbits were lost at the early stage of the experiment and were excluded from the follow-up studies. One rabbit
123 had a cardiac arrest at the end of the surgical procedure, and the other one was lost three days after the operation. In post

124 mortem necropsy, an injury in the left hemisphere of the cerebral cortex was found.

125

126 **2.3 Applicability of the scaffold**

127

128 The applicability of the scaffold was subjectively evaluated by the surgeons during the surgical procedures. The focus
129 was on intraoperative shaping of the scaffold, possible crumbling of the scaffold during handling, the ability to fully
130 moisten the scaffold with the bone marrow aspirate harvested from the femoral condyle, the ability to fill the defect, and
131 visual evaluation of the bone-scaffold interface. The bone-scaffold interface was evaluated to ascertain whether the
132 contact between the scaffold and bone was tight or not.

133

134 **2.4 Specimen collection**

135

136 The 18 rabbits were randomly divided in groups of six animals and euthanized 4, 12, and 24 weeks after the surgery.
137 Euthanasia was performed with subcutaneous injection of 0.3 mg/kg medetomidine and 35 mg/kg ketamine followed by
138 intracardiac injection of pentobarbital 300 mg/rabbit (Mebunat vet 60 mg/mL, Orion Pharma). The parietal bone blocks
139 including the defects and the intact bone around them were harvested with an EPD diamond coated circular burr.

140

141 **2.5 Radiographic examination**

142

143 After the surgical procedure, a dorsoventral radiograph (Practix 400, Philips, 46 kV and 4.0 mAs) of the skull was taken.
144 The radiographs were used to evaluate the location of the defects and the radiographic opacity of the scaffold.

145 After euthanasia, the harvested bone blocks were radiographed. A dorsoventral projection (46 kV, 4.0 mAs) of the
146 skull was taken. The new bone formation in the empty defect was subjectively evaluated as no new bone formation, a
147 small amount of new bone formation, or obvious new bone formation. Possible fractures, cyst formation, an excessive
148 amount of callus or signs of osteomyelitis were recorded.

149

150 **2.6 Micro-CT imaging**

151

152 A micro-CT study (MicroXCT-400, Zeiss, Pleasanton, CA, USA) was performed on all of the harvested bone blocks
153 before histologic preparation. A tube voltage of 110 kV and a tube current of 91 μ A were selected. From each sample,
154 1600 projections were taken with a 19.97 x 19.97 x 19.97 μ m voxel size. Exposure time was 4 seconds. Projections were
155 reconstructed with the manufacturer's XMReconstructor software. Image processing and analysis were done with Avizo
156 Software (Thermo Fisher Scientific, Waltham, MA, USA).

157

158 2.6.1 Total amount of radiodense material

159

160 The total amount of radiodense material from the scaffold filled defect and the empty defect was assessed from the micro-
161 CT images. A 12 mm in diameter and 4 mm in height cylinder shaped area was manually placed on the center of the defect
162 and used as a volume of interest for the assessment.

163

164 2.6.2 Distribution of radiodense material

165

166 Radiodense material distribution over the defects was evaluated with a novel method (Fig. 1). To create the distribution
167 map, a 3D-image of the skull was flattened to the 2D-image where one pixel represented a column of voxels in a 3D-
168 picture. Each rabbit had its own individual radiodensity scale where 0 was air and 1 was mean radiodensity of the intact
169 calvarian bone around the defect. Each pixel in the 2D-picture had the same radiodensity as the highest value in the 3D-
170 picture voxel column. Eleven measurement lines per defect were measured from the 2D-picture. The length of the
171 measurement line was 14 mm. There were 100 measurement points in each measurement line. Those measurement point
172 areas covered an area of 100 x 1000 μm , and the radiodensity of that area was the mean radiodensity of the all pixels in
173 that area. A total of 1100 measurements per defect were measured. There were 40 μm gap between the measured areas in
174 the measurement lines. Otherwise, the measured areas were in contact with each other. MathLab (The MathWorks, Inc.,
175 Natick, MA, USA) was used to create a graph of the mean radiodensities in each follow-up group (Fig. 2).

176 **2.7 Histological analysis**

177

178 The harvested bone blocks were fixed in 10% buffered formalin, dehydrated in ascending alcohol series, and embedded
179 in methyl methacrylate (MMA). Then, 5 μm thin slices were sectioned from the midline of the defect using a hard tissue
180 microtome (Leica, SM2500) and stained employing Weigert Van Gieson (WVG) and Masson-Goldner Trichrome (MT)
181 methods.

182 The evaluation of the biocompatibility of the scaffold included the subjective grading of implant decomposition,
183 osteogenesis, and histiocytic reaction on the surface of the implant using a four-tier scale (+/- = minimal, + = mild, ++ =
184 moderate and +++ = marked). A descriptive histopathological analysis of the empty defects was then performed.

185

186 **2.8 Statistical analyses**

187

188 A Kolmogorov-Smirnov test was used to test the normal distribution of the data. Mann-Whitney test was used to compare
189 groups at different follow-up times. Bonferroni correction was used. Wilcoxon Signed Rank test was used to compare
190 scaffold groups with the empty defect groups. The tests were two-tailed. A p-value under 0.05 was considered as
191 statistically significant. IBM SPSS (version 23, Armonk, NY, USA) was used for the statistical analyses.

192

193 **3 Results**

194

195 **3.1 Applicability of the scaffold**

196

197 At room temperature, the scaffold material was relatively rigid and easy to cut with a trephine. During handling, however,
198 the material temperature increased close to body temperature, and thereby its elasticity was increased. The increased
199 elasticity of the material enabled easy impregnation of bone marrow aspirate. Furthermore, due to the elasticity of the
200 scaffold, it was easily squeezed and bent into the defect. Therefore, the convex shape of the lateral side of the skull did
201 not complicate the implantation or influence bone scaffold contact. In all scaffold filled defects, the bone-scaffold contact
202 in the interface was tight when visually evaluated after the implantation. No visible particle loosening from the scaffold
203 occurred during the press-cut, during the moistening of the scaffold in a squeezing bag, or during the implantation.

204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243

3.2 Radiographic examination

During the postoperative radiographic examination, the scaffold could not be distinguished from the skull bones in any of the radiographs. The empty defect was visible in 3 out of 18 (17%) rabbits due to a summation of other calvarial structures.

In post-mortem radiographs from the parietal bone blocks, the density of the scaffold-filled defects was comparable with the density of the intact skull next to the defect. The only visible change in the scaffold side was that the structure of the scaffold turned from homogenous to more heterogenous and grainy during the follow-up period. Excessive callus formation, signs of osteomyelitis, or bone cyst formation were not seen in any scaffold-filled defects during the whole study period.

In post mortem radiographs from the bone blocks, the radiodensity of the empty defect increased with time. At 4 weeks, 2 out of 6 defects showed no new bone formation, two had a small amount of new bone formation, and two had obvious new bone formation. At 12 weeks, 2 out of 6 defects showed a small amount of new bone formation, and four had obvious new bone formation. At 24 weeks, all six defects showed obvious new bone formation. Despite the new bone formation, the empty defects in all groups were apparent, and the radiodensity was lower than the density of the scaffold-filled defects or the intact skull next to the defects.

3.3 MicroCT imaging

Typical micro-CT images of bone growth from the scaffold-filled and empty defects are shown in Figure 3.

3.3.1 Total amount of radiodense material

The total amount of radiodense material in the 12 mm calvarian defects analyzed by micro-CT from the volumes of interest are presented in Table 1. The defects filled with β -TCP/PLCL composite scaffold had a similar level of radiodensity at 4 and 12 weeks (31.6% and 30.1%, respectively). However, the total amount of radiodense material decreased significantly ($p = 0.03$) by 22.4% between weeks 12 and 24.

In the empty defects, the radiodense material filled 7.5% of the volume of interest at 4 weeks increasing up to 11.0% and 11.4% at 12 and 24 weeks, respectively. The changes in the amounts of radiodense material were not, however, statistically significant between any of the groups.

The total amount of radiodense material was significantly ($p = 0.028$) higher throughout the follow-up times in the scaffold-filled defects compared with the empty defects.

3.3.2 Distribution of radiodense material

The distribution graph of radiodense material in the scaffold-filled and empty defects presented in Figure 2 shows that the mean radiodensity of the scaffold-filled defects was maintained close to the radiodensity of an intact skull throughout the defect in all groups. Slightly lower radiodensities were seen at 24 weeks.

In the empty defects, the mean radiodensity was lower than that of the intact skull. The radiodensity inside the defects

244 near the edge increased at 12 and 24 weeks, and at 24 weeks also in the middle of the defects.

245

246 **3.4 Histologic evaluation**

247

248 Already at 4 weeks, tissue reaction to the scaffold consisted of a network of tissue trabeculae advancing from the bone
249 walls of the defect into the porous material. The trabeculae were composed of an abundant vascular network,
250 mesenchymal cells with a moderate number of multinucleated giant foreign body cells and macrophages, and even
251 included some small woven bone nidi surrounded by osteoid. In addition, loose cell strands and erythrocytes admixed
252 with the scaffold (Fig. 4a).

253 At 12 and 24 weeks, the trabeculae exhibited a mesenchymal core, occasionally showing osteoblast differentiation
254 and variable vascularization as well as small to moderate-sized woven bone spicules and nidi surrounded by osteoid. The
255 trabeculae were flanked by moderate to marked histiocytic reaction with ample macrophages and multinucleated giant
256 foreign body cells (Table 3; Fig. 4a). At 12, and especially at 24 weeks, osteogenesis proceeded variably along the dural
257 and superficial periosteum further to the trabeculae.

258 Based on histology, the scaffolds showed moderate to marked decomposition already at 4 weeks, further advancing
259 from 12 to 24 weeks. At 12 weeks, the scaffold material was actively degraded, and the scaffold area appeared to be
260 reduced to approximately 50%. At 24 weeks, macrophages and multinucleated giant cells continued to be abundant and
261 the scaffold area reduced, pointing to progressing histological decomposition (Table 3; Fig. 4a).

262 The empty defects seemed to regenerate by intramembranous ossification, osteogenesis mainly proceeding along the
263 dural periosteum (Fig. 4b). At 4 weeks, small mineralized bone islands, osteoid and highly vascularized connective tissue
264 spanned over the defect. At 12 and 24 weeks, mineralized bone with a thin osteoid rim covered approximately 30% to
265 60% of the length of the defect but remained substantially thinner than intact calvarial bone. Notably, muscle and adipose
266 tissue bulged into the defect from the skull surface (Fig. 4b).

267

268 **4 Discussion**

269

270 In our study, the new β -TCP/PLCL scaffold showed osteoconductive properties as previously demonstrated on pure
271 β -TCP granules in calvarial defects of several different species [22-24]. Osteoconductive materials are recommended to
272 be used in conjunction with bone marrow aspirate or with a bone graft, creating material with osteoconductive,
273 osteoinductive, and osteogenic properties [11, 20]. Bone marrow aspirate was used in this study to improve the properties
274 of the osteoconductive material. Mineralized bone and osteoid were not only seen along the scaffold but also inside the
275 scaffold increasingly at all follow-up times. This ability to promote three-dimensional tissue regeneration can most likely
276 be explained by the high porosity of the scaffold (65%), and an average pore size (380 μm) that mimics that of cancellous
277 bone [25]. Previously, Tsuruga et al. [26] showed that an average pore size larger than 300 μm results in higher
278 osteogenesis than smaller pore sizes. In our study, the high porosity and optimal pore size enabled effective vascularization
279 and mesenchymal tissue ingrowth throughout the scaffold already at 4 weeks. The vascularization and thus high
280 oxygenation is needed for tissue ingrowth and new bone formation [27]. A considerable amount of mesenchymal tissue
281 inside the scaffold was also seen at all follow-up times. This is also a relevant finding since the mesenchymal tissue has
282 been shown to have the ability to differentiate into bone tissue [16].

283 During surgery, the moldable β -TCP/PLCL scaffold filled the whole bony defect and seemed to give structural support.

284 This was confirmed in histology since the surrounding muscles and adipose tissues did not invade into the defect. This is
285 an important finding because soft tissues bulging into the defect significantly hinder the bone regeneration process [28].
286 This was also apparent in the empty defects in this study, where bulging of soft tissues occupied the space and only a thin
287 layer of new bone followed the dural periosteum. This finding is in accordance with previous studies where in calvarial
288 defects new bone formation along the dura is reported to be the principal regeneration type [28, 29]. Notably, the scaffold-
289 filled defects also exhibited pronounced dural osteogenesis in addition to bone ingrowth into the porosity of the scaffold,
290 and new bone formation appeared to slow down from 12 to 24 weeks. It is thus possible that the degradation of the
291 material was not fast enough from 4 to 24 weeks to enable enough space for accelerated new bone formation inside the
292 scaffold. Accordingly, new bone formation in scaffolds has been shown to be slower than in β -TCP granule-filled defects
293 because the material decreases the space available for new bone formation [24, 29, 30]. On the other hand, fast degradation
294 of a filling material may lead to premature loss of structural support, and therefore may not lead to desirable or faster new
295 bone formation. Further studies are needed to see the effect of material degradation on bone formation with longer follow-
296 up times.

297 In our study, the rapid invasion of vasculature, mesenchymal tissue, and bone implied that the biocompatibility of the
298 material was good with no signs of adverse reactions, such as purulent inflammation, necrosis or fibrosis around the
299 scaffold material. Typical foreign body reaction with histiocytes, macrophages, and multinucleated giant cells was
300 observed at all time points, especially at 12 and 24 weeks. This reaction is associated with the degradation process of the
301 scaffold and is seen with other materials, such as hydroxyapatite and β -TCP [15, 31-33].

302 The drawback with existing synthetic ceramic or bioactive glass scaffolds is their brittle and hard nature [10, 34].
303 Thus, the intraoperative molding or shaping of these materials is usually difficult [34] and pure ceramics may create
304 excessive stress on the surrounding tissues during implantation and may even cause fissures to the bone cortex [35]. The
305 cohesion between the tissues and pure ceramics is also lower than the cohesion of autografts, which might cause particles
306 to spread around the surgical field during implantation [35, 36]. Grafting near the joints might cause loose particles to
307 migrate between joint surfaces, and thus create third-body wear [37]. In our study, the new β -TCP/PLCL scaffold was
308 easily moldable and adaptable to the anatomical convex contour of the skull, even though the ceramic concentration of
309 the scaffold was 50 weight-%. Because of its elasticity, the scaffold could be compressed during implantation, and it could
310 also be fitted tightly into the defect. There was no visible ceramic particle loosening from the scaffold at any stage of the
311 procedure, i.e., during moistening of the scaffold with the marrow aspirate in a squeezing pouch or during implantation.

312 As shown in a canine calvarial model, pure β -TCB has higher radiodensity than intact bone, and thus the implant area
313 can be easily distinguished from the bone tissue [23]. In this study, the mixture of micro-granule β -TCB and PLCL-
314 polymer produced a composite material with a very similar radiodensity to intact calvarial bone in the radiographs. In
315 fact, the radiodensities of the bone and the scaffold materials were so similar that it was not possible to differentiate them
316 from each other in the micro-CT study. The textural change of the scaffold from homogenous to grainier and heterogenous
317 during the follow-up period was probably due to scaffold degradation and tissue ingrowth. The total amount of radiodense
318 material and the mean radiodensity analyzed by micro-CT, was affected by the non-dissolved β -TCP microgranules in the
319 scaffold-filled defects, and therefore the analysis result is a combination of new bone and the ceramic phase of the scaffold.
320 Sanda et al. [38] reported a similar amount of radiodense material in both 4- and 8-week groups in rabbits with an 8 mm
321 diameter calvarial defect filled with pure β -TCB granules. In their study, histomorphometric analysis confirmed that there
322 was no mass loss of TCP during the 8 weeks. In our study, the decrease of radiodense material in the scaffold-filled defect
323 started between 12 and 24 weeks. This finding is in accordance with the histological evaluation.

324 A 15 mm diameter defect has been classically defined as a critical size defect in a rabbit calvarial [39]. The new bone
325 formation will plateau after 12 weeks in a 15 mm calvarial defect [24, 40, 41]. In this study, a significant increase in new
326 bone formation after 4 weeks was not observed and the total amount of radiodense material in the empty defects plateaued
327 to approximately 11%. Correspondingly, histopathology confirmed that new bone formation proceeded only as a thin
328 layer or islands accompanying the dura. Nowadays, an alternative definition for critical size defect is a defect that will
329 not spontaneously heal during the time of the experiment [28], and therefore smaller defects have also been used in various
330 calvarial defect studies [42-44]. The findings of this study support this definition, and therefore a 12 mm calvarial defect
331 can be considered as a critical size defect in this study.

332

333 **5 Conclusion**

334

335 This study presented the potentiality of a new supercritical CO₂-foamed poly(L-lactide-co-caprolactone) copolymer β -
336 tricalcium phosphate composite scaffold in three-dimensional tissue regeneration in a critical sized rabbit calvarial defect
337 model. β -TCP was successfully utilized in the scaffold to provide an osteoconductive surface for bone ingrowth, and the
338 interconnected pore structure enabled abundant vascularization and full thickness tissue ingrowth throughout the material.
339 The resilient composite structure could be cut to shape and compressed into the bone defect. As a result, the composite
340 scaffold was easier to use and more versatile than most of the available products used for bone regeneration.

341

342 **Acknowledgements**

343 This study was financially supported by the Finnish Funding Agency for Technology and Innovation (40326/13) and by
344 grants from the Finnish Foundation of Veterinary Research and The Finnish Veterinary Foundation. The authors kindly
345 acknowledge DVM Mikael Morelius for the help with surgical procedures.

346 **Compliance with ethical standards**

347 **Conflict of interest**

348 The authors declare that they have no conflict of interest.

349

350

351 **References**

- 352 1. Calori GM, Mazza E, Colombo M, Ripamonti C. The use of bone-graft substitutes in large bone defects: Any specific
353 needs? *Injury*. 2011;42:56–63.
- 354 2. Moore WR, Graves SE, Bain GI. Synthetic bone graft substitutes. *ANZ J Surg*. 2001;71:354–61.
- 355 3. Myeroff C, Archdeacon M. Autogenous bone graft: donor sites and techniques. *J Bone Joint Surg*. 2011;93:2227–36.
- 356 4. Fillingham Y, Jacobs J. Bone grafts and their substitutes. *Bone Join J*. 2016;98:B(1 Suppl A):6–9.
- 357 5. Schnee CL, Freese A, Weil RJ, Marcotte PJ. Analysis of harvest morbidity and radiographic outcome using autograft
358 for anterior cervical fusion. *Spine*. 1997;22:2222–7.
- 359 6. Sawin PD, Traynelis VC, Menezes AH. A comparative analysis of fusion rates and donor-site morbidity for
360 autogeneic rib and iliac crest bone grafts in posterior cervical fusions. *J Neurosurg*. 1998;88:255–65.
- 361 7. Ebraheim NA, Elgafy H, Xu R. Bone-graft harvesting from iliac and fibular donor sites: techniques and
362 complications. *J Am Acad Orthop Surg*. 2001;9:210–8.
- 363 8. Dimitriou R, Mataliotakis GI, Angoules AG, Kanakaris NK, Giannoudis PV. Complications following autologous
364 bone graft harvesting from the iliac crest and using the RIA: A systematic review. *Injury*. 2011;42:3–15.
- 365 9. Bizenjima T, Takeuchi T, Seshima F, Saito A. Effect of poly(lactide-co-glycolide) (PLGA)-coated beta-tricalcium
366 phosphate on the healing of rat calvarial bone defects: a comparative study with pure-phase beta-tricalcium phosphate.
367 *Clin Oral Implants Res*. 2016;27:1360–7.
- 368 10. Hak DJ. The use of osteoconductive bone graft substitutes in orthopaedic trauma. *J Am Acad Orthop Surg*.
369 2007;15:525–36.
- 370 11. Thaler M, Lechner R, Gstöttner M, Kobel C, Bach C. The use of beta-tricalcium phosphate and bone marrow
371 aspirate as a bone graft substitute in posterior lumbar interbody fusion. *Eur Spine J*. 2013;22:1173–82.
- 372 12. Albee FH. Studies in bone growth: Triple calcium phosphate as a stimulus to osteogenesis. *Ann Surg*. 1920;71:32–
373 9.
- 374 13. Zerbo IR, Zijderveld SA, de Boer A, Bronckers AL, de Lange G, ten Bruggenkate CM, et al. Histomorphometry of
375 human sinus floor augmentation using a porous beta-tricalcium phosphate: a prospective study. *Clin Oral Implants Res*.
376 2004;15:724–32.
- 377 14. Zijderveld S, Zerbo I, van den Bergh J, Schulten E, ten Bruggenkate C. Maxillary sinus floor augmentation using a
378 β -tricalcium phosphate (Cerasorb) alone compared to autogenous bone grafts. *Int J Oral Maxillofac Implants*.
379 2005;20:432–40.
- 380 15. Ghanaati S, Barbeck M, Orth C, Willershausen I, Thimm BW, Hoffmann C, et al. Influence of β -tricalcium
381 phosphate granule size and morphology on tissue reaction in vivo. *Acta Biomater*. 2010;6:4476–87.
- 382 16. Zerbo IR, Bronckers AL, de Lange G, Burger EH. Localisation of osteogenic and osteoclastic cells in porous β -
383 tricalcium phosphate particles used for human maxillary sinus floor elevation. *Biomaterials*. 2005;26:1445–51.
- 384 17. Honda M, Yada T, Ueda M, Kimata K. Cartilage formation by cultured chondrocytes in a new scaffold made of
385 poly(L-lactide- ϵ -caprolactone) sponge. *J Oral Maxillofac Surg*. 2000;58:767–75.
- 386 18. Honda M, Morikawa N, Hata K, Yada T, Morita S, Ueda M, et al. Rat costochondral cell characteristics on poly (1-
387 lactide-co- ϵ -caprolactone) scaffolds. *Biomaterials*. 2003;24:3511–9.

- 388 19. Jeong SI, Kim SH, Kim YH, Kim B, Kang SW, Kwon JH, et al. In vivo biocompatibility and degradation behavior
389 of elastic poly(l-lactide-co-ε-caprolactone) scaffolds. *Biomaterials*. 2004;25:5939–46.
- 390 20. Nandi SK, Roy S, Mukherjee P, Kundu B, De DK, Basu D. Orthopaedic applications of bone graft & graft
391 substitutes: a review. *Indian J Med Res*. 2010;132:15–30.
- 392 21. Hernigou P, Desroches A, Queinnee S, Flouzat Lachaniette C, Poignard A, Allain J, et al. Morbidity of graft
393 harvesting versus bone marrow aspiration in cell regenerative therapy. *Int Orthop*. 2014;38:1855–60.
- 394 22. Luvizuto ER, Queiroz TP, Margonar R, Panzarini SR, Hochuli-Vieira E, Okamoto T, et al. Osteoconductive
395 properties of β-tricalcium phosphate matrix, polylactic and polyglycolic acid gel, and calcium phosphate cement in bone
396 defects. *J Craniofac Surg*. 2012;23:e430–3.
- 397 23. Tanuma Y, Matsui K, Kawai T, Matsui A, Suzuki O, Kamakura S, et al. Comparison of bone regeneration between
398 octacalcium phosphate/collagen composite and β-tricalcium phosphate in canine calvarial defect. *Oral Surg Oral Med*
399 *Oral Pathol Oral Radiol*. 2013;115:9–17.
- 400 24. Lappalainen O, Karhula S, Haapea M, Kyllönen L, Haimi S, Miettinen S, et al. Bone healing in rabbit calvarial
401 critical-sized defects filled with stem cells and growth factors combined with granular or solid scaffolds. *Childs Nerv*
402 *Syst*. 2016;32:681–8.
- 403 25. Hernandez CJ. Cancellous bone. In: Murphy W, Black J, Hastings G, editors. *Handbook of biomaterial properties*.
404 New York: Springer-Verlag; 2016. pp 15–21.
- 405 26. Tsuruga E, Takita H, Itoh H, Wakisaka Y, Kuboki Y. Pore size of porous hydroxyapatite as the cell-substratum
406 controls BMP-induced osteogenesis. *J Biochem*. 1997;121:317–24.
- 407 27. Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. *Biomaterials*. 2005;26:5474–91.
- 408 28. Gosain AK, Santoro TD, Song L, Capel CC, Sudhakar PV, Matloub HS. Osteogenesis in calvarial defects:
409 contribution of the dura, the pericranium, and the surrounding bone in adult versus infant animals. *Plast Reconstr Surg*.
410 2003;112:515–27.
- 411 29. Lappalainen O, Karhula SS, Haapea M, Kauppinen S, Finnilä M, Saarakkala S, et al. Micro-CT analysis of bone
412 healing in rabbit calvarial critical-sized defects with solid bioactive glass, tricalcium phosphate granules or autogenous
413 bone. *J Oral Maxillofac Res*. 2016;7:e4.
- 414 30. Jan A, Sándor G, Brkovic B, Peel S, Kim YD, Xiao W, et al. Effect of hyperbaric oxygen on demineralized bone
415 matrix and biphasic calcium phosphate bone substitutes. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*.
416 2010;109:59–66.
- 417 31. Ghanaati S, Barbeck M, Willershausen I, Thimm B, Stuebinger S, Korzinskas T, et al. Nanocrystalline
418 hydroxyapatite bone substitute leads to sufficient bone tissue formation already after 3 months: Histological and
419 histomorphometrical analysis 3 and 6 months following human sinus cavity augmentation. *Clin Implant Dent Relat Res*.
420 2013;15:883–92.
- 421 32. Miron RJ, Zohdi H, Fujioka-Kobayashi M, Bosshardt DD. Giant cells around bone biomaterials: Osteoclasts or
422 multi-nucleated giant cells? *Acta Biomater*. 2016;46:15–28.
- 423 33. Barbeck M, Booms P, Unger R, Hoffmann V, Sader R, Kirkpatrick CJ, et al. Multinucleated giant cells in the
424 implant bed of bone substitutes are foreign body giant cells – New insights into the material-mediated healing process. *J*
425 *Biomed Mater Res A*. 2017;105:1105–11.
- 426 34. Peltola M, Kinnunen I, Aitasalo K. Reconstruction of orbital wall defects with bioactive glass plates. *J Oral*
427 *Maxillofac Surg*. 2008;66:639–46.

- 428 35. van Haaren EH, Smit TH, Phipps K, Wuisman PI, Blunn G, Heyligers IC. Tricalcium-phosphate and hydroxyapatite
429 bone-graft extender for use in impaction grafting revision surgery. *J Bone Joint Surg [Br]*. 2005;87:267–71.
- 430 36. Oakley J, Kuiper JH. Factors affecting the cohesion of impaction bone graft. *J Bone Joint Surg [Br]*. 2006;88:828–
431 31.
- 432 37. Schroeder C, Grupp T, Fritz B, Schilling C, Chevalier Y, Utschneider S, et al. The influence of third-body particles
433 on wear rate in unicondylar knee arthroplasty: a wear simulator study with bone and cement debris. *J Mater Sci Mater*
434 *Med*. 2013;24:1319–25.
- 435 38. Sanda M, Shiota M, Fujii M, Kon K, Fujimori T, Kasugai S. Capability of new bone formation with a mixture of
436 hydroxyapatite and beta-tricalcium phosphate granules. *Clin Oral Implants Res*. 2015;26:1369–74.
- 437 39. Schmitz JP, Hollinger JO. The critical size defect as an experimental model for craniomandibulofacial nonunions.
438 *Clin Orthop Relat Res*. 1986;205:299–308.
- 439 40. Fok T, Jan A, Peel S, Evans AW, Clokie C, Sándor G. Hyperbaric oxygen results in increased vascular endothelial
440 growth factor (VEGF) protein expression in rabbit calvarial critical-sized defects. *Oral Surg Oral Med Oral Pathol Oral*
441 *Radiol Endod*. 2008;105:417–22.
- 442 41. Jan A, Sándor G, Iera D, Mhawi A, Peel S, Evans AW, et al. Hyperbaric oxygen results in an increase in rabbit
443 calvarial critical sized defects. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2006;101:144–9.
- 444 42. Cooper GM, Mooney MP, Gosain AK, Campbell PG, Losee JE, Huard J. Testing the critical size in calvarial bone
445 defects: revisiting the concept of a critical-size defect. *Plast Reconstr Surg*. 2010;125:1685–92.
- 446 43. Borie E, Fuentes R, del Sol M, Oporto G, Engelke W. The influence of FDBA and autogenous bone particles on
447 regeneration of calvaria defects in the rabbit: A pilot study. *Ann Anat*. 2011;193:412–7.
- 448 44. Pelegrine AA, Aloise AC, Zimmermann A, Mello e Oliveira R, Ferreira LM. Repair of critical-size bone defects
449 using bone marrow stromal cells: a histomorphometric study in rabbit calvaria. Part I: Use of fresh bone marrow or
450 bone marrow mononuclear fraction. *Clin Oral Implants Res*. 2014;25:567–72.
- 451

452
453

Table 1. The total amount of radiodense material in the defects measured using micro-CT. The volume of interest was a 12 mm in diameter and 4 mm in height cylinder-shaped area centered in the middle of the defect. SD = standard deviation.


	Scaffold-filled defect			Empty defect		
	N	Mean (SD)	<i>p</i> - values	N	Mean (SD)	<i>p</i> - values
4 weeks	6	31.6% (2.83)	1.011 (4 vs 12) 0.12 (4 vs 24)	6	7.5% (3.23)	0.165 (4 vs 12) 0.165 (4 vs 24)
12 weeks	6	30.1% (2.24)	0.03 (12 vs 24)	6	11.0% (1.30)	2.247 (12 vs 24)
24 weeks	6	22.4% (5.19)		6	11.4% (1.58)	

454
455
456
457

Table 2. Osteogenesis, histiocytic reaction on scaffold surface and scaffold decomposition were graded using a scale from +/- to +++. Number of animals per group was 6.

	+/-, slight	+, mild	++, moderate	+++, marked
Osteogenesis				
4 weeks	4/6	2/6		
12 weeks	2/6	3/6	1/6	
24 weeks	1/6	4/6	1/6	
Histiocytic reaction				
4 weeks		3/6	3/6	
12 weeks				6/6
24 weeks			2/6	4/6
Implant decomposition				
4 weeks			6/6	
12 weeks			2/6	4/6
24 weeks				6/6

458
459



460

461

Fig. 1

462

Method for the radiodensity of the defect. A 2D-figure was created based on the highest radiodensity of a voxel column


463

in a 3D-picture. There were 11 measurement lines going along the defect. In each measurement line, there were 100

464

measurement areas. Each measurement area was given the value of a mean radiodensity of the 250 pixels in the area.


465



466
467

468 **Fig. 2**

469 Mean radiodensities of the defects at 4, 12, and 24 weeks (n = 6). In this analysis, 1 (yellow) is the radiodensity of the
 470 intact skull, and 0 (blue) is the radiodensity of the air. The scaffold-filled area has visually similar radiodensities at the
 471 follow-up times. At 24 weeks, a small decrease in the radiodensity of the scaffold-filled defect (defect turning from yellow
 472 to orange) is seen. In the empty defect, the mean radiodensity is lower than the density of an intact skull. Radiodensity
 473 increase inside the defect around the edges at 12 and 24 weeks and also in the middle of the defect at 24 weeks.



474

475

Fig. 3

476

Micro-CT image from different animals at 4, 12, and 24 weeks. In the empty defect there are small islands of bone inside

477

the defect. Pictures from the top and bottom side and also in the middle of the defect show typical bone regeneration at

478


different times in the scaffold-filled defects. Bone has been manually colored to yellow in the sliced picture. The new

479

bone formation is advancing along the dura and periosteum, but advanced new bone formation inside of the scaffold was

480

seen when the follow-up time increased. The scaffold-bone interface looked tight in all groups.



481

482 **Fig. 4**

483

484 **A:** Histology of the bone regeneration, ingrowth into the scaffold and typical tissue reactions at 4, 12, and 24 weeks. At 4
 485 weeks, the scaffold is invaded by mesenchymal cell strands (arrows), ample vasculature/erythrocytes (open arrow heads),
 486 and some multinucleated giant cells (red arrow heads). Lacy to opalescent scaffold material (open arrows) is poorly
 487 discernible. At 12 and 24 weeks, invading tissue trabeculae show mesenchymal core and variable vascularization as well
 488 as mineralized bone islands (green) surrounded by osteoid (closed arrow heads). The trabeculae are flanked by moderate
 489 to marked histiocytic reaction with large multinucleated giant cells. **B:** Histology of the empty defects at 4, 12, and 24
 490 weeks. The empty defects regenerate by intramembranous ossification, osteogenesis mainly proceeding along the dural
 491 periosteum (asterisk) showing mineralized bone islands, osteoid/ossifying mesenchyme (closed arrow heads) in
 492 vascularized connective tissue. Muscle and adipose tissue (red asterisks) bulge into the defect. MT stain, objective
 493 magnification 5x.

494